Dermatology

In her SDPA Fall Dermatology Conference interview, Holzem highlights key warning signs for a variety of dermatologic conditions requiring hospital admission.

This interview at the SDPA Fall Dermatology Conference highlights several topics covered in sessions presented by Trotter.

Two large cohort studies found greater infection and implant-related risks in patients with atopic skin conditions after major surgeries.

This interview at SDPA highlights Gatti's views on the impact of technology on radiology, pathology, and dermatology.

This post-hoc analysis highlights nemolizumab’s long-term efficacy and safety in adolescents with moderate-to-severe atopic dermatitis.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and new Crohn's disease guidelines, in this week's essential news roundup.

Following the Skin of Color Society's (SOCS) 8th Annual Media Day, a Skin of Color Savvy podcast episode will be released highlighting the event.

The Psoriasis Study of Health Outcomes (PSoHO) was designed as a 36-month, non-interventional, international cohort study of patients with psoriasis.

Late-breaking REZOLVE-AD data show rezpegaldesleukin 24 μg/kg improves skin and asthma, supporting its potential in moderate-to-severe atopic dermatitis.

In this analysis, investigators examined the efficacy of baricitinib in terms of its impact on disease activity and progression of frontal fibrosing alopecia.

These data highlight a super-response following treatment with delgocitinib cream 20 mg/g in a subgroup of patients with moderate to severe CHE.

Becker recapped hot topics of discussion during a recent HCPLive clinical forum.

The SCALE-UP study, assessing patients with atopic dermatitis treated with upadacitinib, points to rapid real‐world efficacy findings on this medication.

New phase 2 data reveals povorcitinib effectively reduces itch and hives in chronic spontaneous urticaria, showing promise as a treatment option.

At the Fall Clinical Dermatology Conference, this session provided clinical pearls to clinicians in the pediatric dermatology space.

In this episode, the topic of navigating the holiday season and balancing a thriving medical career and a fulfilling family life are highlighted.

This November 18 episode explores early detection, diagnosis, and management of scarring alopecias and hair-care–related hair loss in patients of color.

A phase 3b study in patients with skin of color found lebrikizumab provides reliable efficacy and safety for treating moderate-to-severe AD.

New ACAAI 2025 data show lebrikizumab improves disease control, quality of life, and work productivity in patients of skin of color with moderate to severe atopic dermatitis.

These topline results from the ADHAND trial highlight tralokinumab’s use in adults with atopic dermatitis with moderate-to-severe hand involvement.

The FDA acceptance of Arcutis's supplemental New Drug Application (sNDA) was announced for roflumilast cream 0.3% (Zoryve).

This Fall Clinical Dermatology Conference interview features Peter Lio, MD, discussing takeaways from several of his sessions at the meeting.

Here, we spotlighted 4 late-breaker studies featured in our ACAAI 2025 coverage, along with 2 phase 3 trials.

After his sessions on TYK2 Inhibitors for psoriasis and on palmoplantar pustulosis, Vender discussed several key insights in this interview.

In this Q&A, Soong discusses phase 2 results on povorcitinib, a JAK1 inhibitor that provides rapid relief from chronic spontaneous urticaria symptoms.